Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Basic Lipid Panel Faulted in Heart Disease Risk

By LabMedica International staff writers
Posted on 23 Apr 2013
The basic lipid panel could be leaving millions at risk due to errors in estimation of low-density lipoprotein (LDL) cholesterol levels, even though it is relied upon for more than 85% of adult cholesterol testing each year.

The accuracy of the Friedewald equation in calculated LDL cholesterol measurement using the traditional basic lipid panel or standard cholesterol test, has been compared to directly measured LDL-C in the comprehensive commercial VAP Lipid Panel.

Scientists at Johns Hopkins Ciccarone Center (Baltimore, MD, USA) working with colleagues from different institutes, examined consecutive lipid profiles from a clinical sample of 1,340,614 US adults who were 18 years of age or older and whose blood sample underwent vertical spin density gradient ultracentrifugation of cholesterol from 2009 to 2011. More...
The mean age of the patients was 59 years and 52% were women.

Lipid measurements included inverted rate zonal, single vertical spin, density gradient ultracentrifugation by the Vertical Auto Profile (VAP) technique (Atherotech Diagnostics Lab; Birmingham, AL, USA). This technique directly measures LDL-C, very low density lipoprotein cholesterol (VLDL-C), intermediate-density lipoproteins cholesterol (IDL-C), lipoprotein (a) cholesterol (Lp(a)-C), and high density lipoprotein cholesterol (HDL-C). VAP accuracy was examined yearly from 2007 to 2012.

The results of the study showed that the basic lipid panel underestimated risk in 23% to 59% of patients with Friedewald estimated LDL cholesterol levels below 70 mg/dL and triglycerides above 150 mg/dL, which could result in under treatment of high-risk patients.

The authors concluded that the Friedewald equation tends to underestimate LDL-C mainly when accuracy is most crucial, especially if triglycerides are equal to or greater than 150 mg/dL. Friedewald estimation commonly classifies LDL-C as less than 70 mg/dL despite directly measured levels equal to or greater than 70 mg/dL, and therefore additional evaluation is warranted in high-risk patients.

Steven R. Jones, MD, the senior investigator said, "It's the first time we've compared LDL cholesterol measurements using the Friedewald calculation to the density gradient ultracentrifugation method, which directly measures LDL cholesterol. What's important in this study is that Friedewald and direct LDL cholesterol are most different, with Friedewald LDL generally lower than direct LDL, when accuracy is most crucial in patients with LDL cholesterol levels in the high-risk treatment target range and elevated triglycerides." The study was published on March 20, 2013, in the Journal of the American College of Cardiology.

Related Links:
Johns Hopkins Ciccarone Center
Atherotech Diagnostics




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.